Brk Inhibitory Compound Selective Kinase Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds do not selectively inhibit Breast tumor kinase (Brk), a kinase involved in various cancers, limiting effective therapeutic options for Brk-related diseases.
Innovation Solution
A compound represented by general formula (I), which has Brk inhibitory activity and high selectivity compared to other kinases, is developed to serve as a preventive and therapeutic agent for cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used, then general kinase inhibition may occur, but selective inhibition of Brk is not achieved
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (pyrazolo[3,4-d]pyrimidine core with particular substituent patterns) that create localized interactions with Brk's unique binding pocket. The compound's specific arrangement of functional groups (amino groups at positions 4 and 6, N6-substituted pyrazolyl group) enables selective recognition of Brk's ATP-binding site, achieving high selectivity (greater than 100-fold preference for Brk over other kinases) while maintaining reliable inhibition of Brk activity
Solution Approach 2:
The patent employs parameter changes by systematically varying the substituent parameters on the pyrazolo[3,4-d]pyrimidine core structure. By optimizing the R1, R2, R3, R4, and R5 substituents (including different halogens, alkyl groups, and their positions), the compound achieves optimal binding affinity and selectivity for Brk. This structural parameter optimization enables the compound to distinguish Brk from other kinases based on subtle differences in their ATP-binding sites
2Reliability
If a highly selective Brk inhibitor is developed, then therapeutic efficacy for Brk-related cancers is improved, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent achieves universality by designing a compound where the pyrazolo[3,4-d]pyrimidine core structure serves multiple functions: it provides the essential scaffold for kinase ATP-binding site interaction, enables selective recognition of Brk through specific substituent positioning, and maintains drug-like properties for pharmacological activity. This multi-functional design allows the single compound to achieve selective Brk inhibition with therapeutic efficacy without requiring complex molecular assemblies
Data Source
AI summary
The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.